# Lauren A. Byers

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/lauren-a-byers/

## Facts

| Field | Value |
| --- | --- |
| Citations | 26,458 |
| Field | Lung Cancer Research Studies |
| h-index | 76 |
| i10-index | 188 |
| Last Known Institution | The University of Texas MD Anderson Cancer Center |
| OpenAlex ID | https://openalex.org/A5067755477 |
| ORCID iD | 0000-0002-0780-2677 |
| Works | 872 |

## Researcher papers

Showing 12 of 21.

- [Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data](https://scholariq.org/papers/molecular-subtypes-of-small-cell-lung-cancer-a-synthesis-of-human-and-mouse/)
- [An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance](https://scholariq.org/papers/an-epithelial-mesenchymal-transition-gene-signature-predicts-resistance-to-egfr/)
- [Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression](https://scholariq.org/papers/metastasis-is-regulated-via-microrna-200-zeb1-axis-control-of-tumour-cell-pd-l1/)
- [Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities](https://scholariq.org/papers/patterns-of-transcription-factor-programs-and-immune-pathway-activation-define/)
- [Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i> -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities](https://scholariq.org/papers/co-occurring-genomic-alterations-define-major-subsets-of-i-kras-i-mutant-lung/)
- [Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer](https://scholariq.org/papers/targeting-dna-damage-response-promotes-antitumor-immunity-through-sting-mediated/)
- [Small cell lung cancer: Where do we go from here?](https://scholariq.org/papers/small-cell-lung-cancer-where-do-we-go-from-here/)
- [Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial](https://scholariq.org/papers/neoadjuvant-nivolumab-or-nivolumab-plus-ipilimumab-in-operable-non-small-cell/)
- [A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition](https://scholariq.org/papers/a-patient-derived-pan-cancer-emt-signature-identifies-global-molecular/)
- [Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1](https://scholariq.org/papers/proteomic-profiling-identifies-dysregulated-pathways-in-small-cell-lung-cancer/)
- [Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study](https://scholariq.org/papers/rovalpituzumab-tesirine-a-dll3-targeted-antibody-drug-conjugate-in-recurrent/)
- [Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome](https://scholariq.org/papers/effect-of-kras-oncogene-substitutions-on-protein-behavior-implications-for/)

## Researcher topics

- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [RNA modifications and cancer](https://scholariq.org/topics/rna-modifications-and-cancer/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Neuroendocrine Tumor Research Advances](https://scholariq.org/topics/neuroendocrine-tumor-research-advances/)

## Researcher university

- [The University of Texas MD Anderson Cancer Center](https://scholariq.org/institutions/the-university-of-texas-md-anderson-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.